Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should children with osteogenesis imperfecta be treated with bisphosphonates?

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 14–15 (2006)Cite this article

boxed-textGatti D et al. (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20: 758–763

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Whyte MP et al. (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457–463

    Article  CAS  Google Scholar 

  2. Sakkers R et al. (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363: 1427–1431

    Article  CAS  Google Scholar 

  3. Glorieux FH et al. (2004) Alendronate in the treatment of pediatric osteogenesis imperfecta. J Bone Miner Res 19 (Suppl 1): 1043

    Google Scholar 

  4. Letocha AD et al. (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20: 977–986

    Article  CAS  Google Scholar 

  5. Uveges TE et al. (2004) Alendronate treatment of Brtl mouse model for osteogenesis imperfecta improved bone geometry and loading before fracture but decreased bone material quality and alters osteoblast morphology. Eur J Hum Genet 12 (Suppl 1): 1208

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Chief of the Bone and Extracellular Matrix Branch, National Institute of Child Heath and Disease, NIH, Bethesda, MD, USA

    Joan C Marini

Authors
  1. Joan C Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan C Marini.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marini, J. Should children with osteogenesis imperfecta be treated with bisphosphonates?. Nat Rev Endocrinol 2, 14–15 (2006). https://doi.org/10.1038/ncpendmet0075

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0075

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing